At Sanford Burnham Prebys Medical Discovery Institute in San Diego, scientists have uncovered a hidden vulnerability in aggressive cancers: their insatiable hunger for cholesterol. When tumors with a mutation in the TP53 gene—which governs roughly half of all cancers—are cut off from cholesterol transport, they starve and die, even when the cholesterol itself remains plentiful.
The finding, published in Science Advances through collaboration between Sanford Burnham Prebys and the University of Illinois Chicago, zeroes in on a family of enzymes called phosphatidylinositol-5-phosphate 4-kinases, or PI5P4Ks. These tiny molecular transporters act like traffic controllers, moving cholesterol through cancer cells in ways that normal cells never require. Without them, cholesterol accumulates uselessly in the cell's interior—a metabolic jam that halts tumor growth.
The research carries particular urgency for breast cancer patients. Brooke Emerling, director of the Cancer Metabolism and Microenvironment Program at the institute, notes that TP53 mutations appear in more than 84% of triple-negative breast cancers and three of every four HER2-amplified breast cancers, subtypes notoriously difficult to treat with standard therapies. "We need more ways to treat cancers with this common mutation," Emerling said.
The puzzle began when researchers studied mice genetically engineered to lose the TP53 gene—normally fatal within four to eight months as cancers inevitably develop. But when these same animals also lost the PI5P4K enzymes, something remarkable happened: tumors never formed at all. The mice remained disease-free throughout their lives. Cholesterol, as it turned out, was central to understanding why.
Ryan Loughran, a postdoctoral researcher in Emerling's lab, and his colleagues conducted experiments showing that PI5P4Ks control the position of lysosomes—cellular compartments that store cholesterol. In cancer cells carrying TP53 mutations, these lysosomes cluster near the outer cell membrane, positioning their cholesterol cargo next to crucial growth-signaling molecules. The most important of these is mTORC1, a powerful enzyme that triggers cell expansion and runs catastrophically out of control in cancer.
It is a matter of cellular geography. When PI5P4Ks vanish, lysosomes drift toward the cell's interior, staying near the nucleus. From this distant position, they lose contact with mTORC1 and the membrane-bound signaling machinery that screams "grow!" Cancer cells in this situation cannot access the growth signals they need, even though cholesterol itself sits nearby—untouched and useless, like supplies arriving at the wrong address.
"When lysosome positioning is biased towards the cell nucleus, mTORC1 activation is suppressed," Loughran explained. "This connects directly to our previous work, where we found that the loss of these kinases triggers starvation-like states in cancer cells."
The discovery opens a direct therapeutic path: block PI5P4Ks, reposition the cholesterol depots, and starve cancers with TP53 mutations without actually removing cholesterol from the body. This specificity could spare patients the side effects of blunt cholesterol-lowering approaches. For the millions of people carrying these hard-to-treat cancers, the research suggests that vulnerability was hiding in plain sight—not in what cancer cells eat, but in where they keep their food.